SEC INSIDER TRANSACTIONS

RESMED INC (RMD) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

RMD · RESMED INC

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Stale snapshot · Covered: filings 2026-10-15 to 2026-11-13 · 7 filings · fetched 2026-11-13T19:57:04Z

View six-calendar-month insider history →

Recent reported activity

0purchase rows on this page

2sale rows on this page

14matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-11-11Filed 2026-11-13	Rider Michael JOfficer · Global General Counsel Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2025. F2 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2024. F3 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023. F4 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. F5 Includes 41.7624 shares of Resmed stock purchased on Oct 30, 2026 through the Resmed Employee Stock Purchase Plan. References: F4, F5	F WithholdingResMed Common Stock · Non-derivative	172.993D	234.11	Direct	Form 4 ↗0000943819-26-000096
2026-11-11Filed 2026-11-13	Rider Michael JOfficer · Global General Counsel Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2025. F2 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2024. F3 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023. F4 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. F5 Includes 41.7624 shares of Resmed stock purchased on Oct 30, 2026 through the Resmed Employee Stock Purchase Plan. References: F3	F WithholdingResMed Common Stock · Non-derivative	724.414D	234.11	Direct	Form 4 ↗0000943819-26-000096
2026-11-11Filed 2026-11-13	Rider Michael JOfficer · Global General Counsel Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2025. F2 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2024. F3 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023. F4 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. F5 Includes 41.7624 shares of Resmed stock purchased on Oct 30, 2026 through the Resmed Employee Stock Purchase Plan. References: F2	F WithholdingResMed Common Stock · Non-derivative	498.624D	234.11	Direct	Form 4 ↗0000943819-26-000096
2026-11-11Filed 2026-11-13	Rider Michael JOfficer · Global General Counsel Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2025. F2 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2024. F3 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023. F4 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. F5 Includes 41.7624 shares of Resmed stock purchased on Oct 30, 2026 through the Resmed Employee Stock Purchase Plan. References: F1	F WithholdingResMed Common Stock · Non-derivative	547.469D	234.11	Direct	Form 4 ↗0000943819-26-000096
2026-11-11Filed 2026-11-13	Gill HarjitDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2025. References: F1	F WithholdingResMed Common Stock · Non-derivative	35.731D	234.11	Direct	Form 4 ↗0000943819-26-000098
2026-11-11Filed 2026-11-13	De Witte JanDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2025. References: F1	F WithholdingResMed Common Stock · Non-derivative	59.981D	234.11	Direct	Form 4 ↗0000943819-26-000100
2026-11-11Filed 2026-11-13	FARRELL PETER CDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2025. References: F1	F WithholdingResMed Common Stock · Non-derivative	169.142D	234.11	Direct	Form 4 ↗0000943819-26-000102
2026-11-11Filed 2026-11-13	Bloomer AaronOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 6/1/2026. References: F1	F WithholdingResMed Common Stock · Non-derivative	1,095.137D	234.11	Direct	Form 4 ↗0000943819-26-000104
2026-11-09Filed 2026-11-12	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $231.7956 - $237.600. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year F4 Represents date options first become exercisable. Options vest 1/3 per year References: F1, F4	M Exercise / conversionResMed Common Stock Options · Derivative	4,310D	0	Direct	Form 4 ↗0000943819-26-000091
2026-11-09Filed 2026-11-12	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $231.7956 - $237.600. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year F4 Represents date options first become exercisable. Options vest 1/3 per year References: F1, F3	M Exercise / conversionResMed Common Stock Options · Derivative	683D	0	Direct	Form 4 ↗0000943819-26-000091
2026-11-09Filed 2026-11-12	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $231.7956 - $237.600. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year F4 Represents date options first become exercisable. Options vest 1/3 per year References: F1, F2	S Sale (market/private)ResMed Common Stock · Non-derivative	4,993D	235.3473	Direct	Form 4 ↗0000943819-26-000091
2026-11-09Filed 2026-11-12	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $231.7956 - $237.600. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year F4 Represents date options first become exercisable. Options vest 1/3 per year References: F1	M Exercise / conversionResMed Common Stock · Non-derivative	4,310A	146.34	Direct	Form 4 ↗0000943819-26-000091
2026-11-09Filed 2026-11-12	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $231.7956 - $237.600. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year F4 Represents date options first become exercisable. Options vest 1/3 per year References: F1	M Exercise / conversionResMed Common Stock · Non-derivative	683A	146.34	Direct	Form 4 ↗0000943819-26-000091
2026-10-23Filed 2026-10-26	Rider Michael JOfficer · Global General Counsel Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted February 28, 2025. References: F1	S Sale (market/private)ResMed Common Stock · Non-derivative	400D	255	Direct	Form 4 ↗0000943819-26-000086

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.